<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39399820</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2590-1362</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Vaccine: X</Title><ISOAbbreviation>Vaccine X</ISOAbbreviation></Journal><ArticleTitle>Time-course analysis of antibody and cytokine response after the third SARS-CoV-2 vaccine dose.</ArticleTitle><Pagination><StartPage>100565</StartPage><MedlinePgn>100565</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100565</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvacx.2024.100565</ELocationID><Abstract><AbstractText>The widespread administration of an additional dose of the SARS-CoV-2 vaccine has been promoted across adult populations, demonstrating a robust immune response against COVID-19. Longitudinal studies provide crucial data on the durability of immune response after the third vaccination. This study aims to explore the antibody response, neutralizing activity, and cytokine response against the SARS-CoV-2 ancestral strain (wild-type) and its variants during the timeline before and after the administration of the third vaccine dose. Anti-spike antibody titers and neutralizing antibodies blocking ACE2 binding to spike antigens were measured in 62 study participants at baseline, and on days 7, 21, and 180 post-vaccination. Cytokine levels were assessed at the same points except for day 180, with an additional measurement on day 3 post-vaccination. The analysis revealed no substantial variation in anti-spike antibody titer against the SARS-CoV-2 ancestral strain between the pre-vaccination phase and three days following the third dose. However, a significant nine-fold increase in these titers was observed by day 7, maintained until day 21. Although a decrease was observed by day 180, all participants still had detectable antibody levels. A similar trend was noted for neutralizing antibodies, with a four-fold rise by day 7 post-vaccination. At day 180, a diminution of neutralizing antibody titers was evident for both wild-type and all variants, including Omicron subvariant. A transient increase in cytokine activity, notably involving components of the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway, such as CXCL10 and IL-10, was observed within three days after the third dose. This study underscores a distinct amplification of humoral immune response seven days following the third SARS-CoV-2 vaccine dose and observes a decline in neutralizing antibody titers 180 days following the third dose, thus indicating the temporal humoral effectiveness of booster vaccination. A short-term cytokine surge, notably involving the JAK/STAT pathway, highlights the dynamic immune modulation post-vaccination.</AbstractText><CopyrightInformation>© 2024 The Authors. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyeon Hwa</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hye Kyung</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics and Physiology, National Institute of Diabetes, Digestive and Kidney Diseases, US National Institutes of Health, Bethesda, MD 20892, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hennighausen</LastName><ForeName>Lothar</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics and Physiology, National Institute of Diabetes, Digestive and Kidney Diseases, US National Institutes of Health, Bethesda, MD 20892, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furth</LastName><ForeName>Priscilla A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics and Physiology, National Institute of Diabetes, Digestive and Kidney Diseases, US National Institutes of Health, Bethesda, MD 20892, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Heungsup</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huh</LastName><ForeName>Jin Won</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Vaccine X</MedlineTA><NlmUniqueID>101748769</NlmUniqueID><ISSNLinking>2590-1362</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibody response</Keyword><Keyword MajorTopicYN="N">Cytokine response</Keyword><Keyword MajorTopicYN="N">JAK/STAT pathway</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Third dose</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>7</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39399820</ArticleId><ArticleId IdType="pmc">PMC11470517</ArticleId><ArticleId IdType="doi">10.1016/j.jvacx.2024.100565</ArticleId><ArticleId IdType="pii">S2590-1362(24)00138-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou P., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrotri M., et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021;398(10298):385–387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285117</ArticleId><ArticleId IdType="pubmed">34274038</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouwels K.B., et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021;27(12):2127–2135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8674129</ArticleId><ArticleId IdType="pubmed">34650248</ArticleId></ArticleIdList></Reference><Reference><Citation>Gómez C.E., Perdiguero B., Esteban M. Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19. Vaccines. 2021;9(3):243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7999234</ArticleId><ArticleId IdType="pubmed">33799505</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.K., et al. mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron. Cell Rep. 2022;39(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8947943</ArticleId><ArticleId IdType="pubmed">35395191</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.K., et al. Heterologous ChAdOx1-BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses that includes Omicron. iScience. 2022;25(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9132682</ArticleId><ArticleId IdType="pubmed">35637788</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan H.Z., et al. A study on pregenomic RNA and factors related to hepatitis B virus infection based on real world. Front Public Health. 2022;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240609</ArticleId><ArticleId IdType="pubmed">35784246</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon S.R., et al. Strong SARS-CoV-2 antibody response after booster dose of BNT162b2 mRNA vaccines in uninfected healthcare workers. JKMS. 2022;37(19):e135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110264</ArticleId><ArticleId IdType="pubmed">35578582</ArticleId></ArticleIdList></Reference><Reference><Citation>Nah E.H., et al. SARS-CoV-2 antibody response and sustainability after a third dose of BNT162b2 in healthcare workers at health promotion centers. Viruses. 2023;15(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10055753</ArticleId><ArticleId IdType="pubmed">36992460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.Y., et al. Vaccine effectiveness against severe disease and death for patients with COVID-19 during the delta-dominant and omicron-emerging periods: a K-COVE study. J Korean Med Sci. 2023;38(11):e87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10027545</ArticleId><ArticleId IdType="pubmed">36942395</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert P.B., et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogensen T.H., Paludan S.R. Molecular pathways in virus-induced cytokine production. Microbiol Mol Biol Rev. 2001;65(1):131–150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC99022</ArticleId><ArticleId IdType="pubmed">11238989</ArticleId></ArticleIdList></Reference><Reference><Citation>Barda N., et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093–2100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8555967</ArticleId><ArticleId IdType="pubmed">34756184</ArticleId></ArticleIdList></Reference><Reference><Citation>Saciuk Y., et al. Effectiveness of a third dose of BNT162b2 mRNA vaccine. J Infect Dis. 2022;225(1):30–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689889</ArticleId><ArticleId IdType="pubmed">34726239</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D.S., et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211.</Citation><ArticleIdList><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley S.F., et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021;384(6):533–540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781098</ArticleId><ArticleId IdType="pubmed">33369366</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., et al. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial. J Infect. 2022;84(6):795–813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8993491</ArticleId><ArticleId IdType="pubmed">35405168</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilboa M., et al. Durability of immune response after COVID-19 booster vaccination and association with COVID-19 omicron infection. JAMA Netw Open. 2022;5(9):e2231778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9478782</ArticleId><ArticleId IdType="pubmed">36107426</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X.M., et al. A third dose of an inactivated vaccine dramatically increased the levels and decay times of anti-SARS-CoV-2 antibodies, but disappointingly declined again: a prospective, longitudinal, cohort study at 18 serial time points over 368 days. Front Immunol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9098946</ArticleId><ArticleId IdType="pubmed">35572536</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng G., et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022;22(4):483–495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8651254</ArticleId><ArticleId IdType="pubmed">34890537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.K., et al. Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients. iScience. 2022;25(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9561373</ArticleId><ArticleId IdType="pubmed">36267551</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., et al. No correlation of neutralizing antibody titers against the Omicron variant after a booster dose of COVID-19 vaccines with subsequent breakthrough Omicron infections among healthcare workers. J Infect. 2022;85(6):e177–e180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9548087</ArticleId><ArticleId IdType="pubmed">36223860</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch D.H. Covid-19 vaccines - immunity, variants, boosters. N Engl J Med. 2022;387(11):1011–1020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9454645</ArticleId><ArticleId IdType="pubmed">36044620</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates T.A., et al. An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants. JCI Insight. 2023;8(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10077480</ArticleId><ArticleId IdType="pubmed">36701200</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates T.A., et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol. 2022;7(68):eabn8014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8939472</ArticleId><ArticleId IdType="pubmed">35076258</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilz S., et al. SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity. Environ Res. 2022;209</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8824301</ArticleId><ArticleId IdType="pubmed">35149106</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.K., et al. Prior vaccination exceeds prior infection in eliciting innate and humoral immune responses in omicron infected outpatients. Front Immunol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240221</ArticleId><ArticleId IdType="pubmed">35784346</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R., Kershaw N.J., Babon J.J. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci. 2018;27(12):1984–2009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6237706</ArticleId><ArticleId IdType="pubmed">30267440</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchingo J.M., et al. Quantitative analysis of how Myc controls T cell proteomes and metabolic pathways during T cell activation. Elife. 2020;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7056270</ArticleId><ArticleId IdType="pubmed">32022686</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(3):203–208.</Citation><ArticleIdList><ArticleId IdType="pubmed">32164089</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum D.C., June C.H. Cytokine storm. N Engl J Med. 2020;383(23):2255–2273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari H., et al. The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Life Sci. 2020;258</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7387997</ArticleId><ArticleId IdType="pubmed">32735885</ArticleId></ArticleIdList></Reference><Reference><Citation>Knabl L., et al. BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 Beta variant. Commun Med (Lond) 2022;2(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9029844</ArticleId><ArticleId IdType="pubmed">35465056</ArticleId></ArticleIdList></Reference><Reference><Citation>Aota K., et al. Distinct regulation of CXCL10 production by cytokines in human salivary gland ductal and acinar cells. Inflammation. 2018;41(4):1172–1181.</Citation><ArticleIdList><ArticleId IdType="pubmed">29549479</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.K., Jung O., Hennighausen L. JAK inhibitors dampen activation of interferon-stimulated transcription of ACE2 isoforms in human airway epithelial cells. Commun Biol. 2021;4(1):654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8172581</ArticleId><ArticleId IdType="pubmed">34079039</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi C., et al. Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021;36(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8299183</ArticleId><ArticleId IdType="pubmed">34352226</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahtinen S., et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol. 2022;23(4):532–542.</Citation><ArticleIdList><ArticleId IdType="pubmed">35332327</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.K., et al. Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination. Blood Adv. 2023;7(10):2214–2227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906673</ArticleId><ArticleId IdType="pubmed">36630562</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward H., et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat Commun. 2022;13(1):907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8850615</ArticleId><ArticleId IdType="pubmed">35173150</ArticleId></ArticleIdList></Reference><Reference><Citation>Anastassopoulou C., et al. Age and sex associations of SARS-CoV-2 antibody responses post BNT162b2 vaccination in healthcare workers: A mixed effects model across two vaccination periods. PLoS One. 2022;17(4):e0266958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9053797</ArticleId><ArticleId IdType="pubmed">35486622</ArticleId></ArticleIdList></Reference><Reference><Citation>Grupel D., et al. Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination. Vaccine. 2021;39(38):5337–5340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8354802</ArticleId><ArticleId IdType="pubmed">34393018</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciarambino T., Para O., Giordano M. Immune system and COVID-19 by sex differences and age. Womens Health (Lond) 2021;17 17455065211022262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8188967</ArticleId><ArticleId IdType="pubmed">34096383</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>